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Abstract. Recent studies have identified the molecular defect underlying autosomal dominant osteogenesis imperfecta (OI) type
V. Unlike all other OI types, which are characterized by high genetic heterogeneity, OI type V appears consistently associated
to a unique de novo C>T transition within the 5′ UTR of the IFITM5 gene. Although the precise frequency of OI type V is not
known, this recurrent base substitution may well represent a mutational hotspot in the human genome. We show that it occurs
at a CpG dinucleotide that is highly methylated in several tissues and particularly in the sperm DNA, suggesting a mutational
mechanism common to other de novo recurrent dominant mutations.
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1. Introduction
Osteogenesis imperfecta (OI) is a heterogeneous
group of disorders, which share common features such
as bone fragility, frequent fractures, deformities of the
spine and limbs.
The current classification comprises five forms (OI
types I–V) with autosomal dominant (AD) inheritance
and eight rare forms (OI types VI–XIII) with recessive
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University of Verona, Strada le Grazie, 8 37134 Verona, Italy. Tel.:
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inheritance. The majority of OI cases falls within types
I–IV, caused by dominant mutations in either of the
type I collagen coding genes (COL1A1 and COL1A2)
[1, 2]. OI type V (MIM 610967), which is also charac-
terized by AD inheritance, has distinguishing clinical
and radiological features: absence of blue sclerae,
absence of dentinogenesis imperfecta, propensity to
hyperplastic callus formation, calcification of the fore-
arm interosseous membrane, radial-head dislocation,
and a subphyseal-metaphyseal radiodense line [3]. The
disease gene, coding for IFITM5 (interferon -induced
transmembrane protein 5) was identified recently. A
c.-14C>T recurrent mutation in its 5’UTR has been
found in >60 patients so far [4–7]. The de novo
2146-4596/14/$27.50 © 2014 – IOS Press and the authors. All rights reserved
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Fig. 1. (A) Radiographs of the patient’s limbs showing fractures and interosseous membrane calcifications development as well as the initial
evidence of periosteal calcification (arrows) Radial head dislocation is visible on the forearm anteroposterior view. (B) Sequence of patient’s
genomic DNA obtained from leukocytes showing C/T heterozygosity at −14 nt within the 5’UTR region of IFITM5.
C>T substitution which occurs at a CpG dinucleotide
and creates an upstream ATG codon in frame with
the canonical start codon, might be the prevailing,
if not the only, causative mutation for type V OI.
The mutation adds five residues to the N-terminus of
the IFITM5 transmembrane protein, possibly with a
gain-of-function effect. We have found the same base
substitution in a young male patient showing typical
radiographic and clinical features of type V OI. We then
decided to investigate this mutational hotspot further
within the IFITM5 gene in relation to the methylation
state of c.-14C.
2. Case report
The proband is a 7-year-old boy born at term to non-
consanguineous unaffected parents, after a pregnancy
characterized by mild oligohydramnios. His weight
was on the 10th percentile (2.600 g at 38 wk of ges-
tational age). He was diagnosed as affected with OI
soon after birth because of a forearm fracture. He was
started and currently is on bisphosphosphonate (Ner-
idronate) treatment because of high fracture rate. He
was classified as OI type V only after age 5 because of
pathognomonic outcomes such as interosseous mem-
brane calcifications, the initial evidence of periosteal
calcification and the emergence of hyperplastic cal-
lous formation (Fig. 1A). His growth and his bone
density are around the 10–25th percentile. As for bio-
logical data he has elevated bone alkaline phosphatase
(>120g/L; mean value in our age/gender matched
controls: 70 ± 30g/L) and high carboxy-terminal
collagen cross-links level (0.888 nmol/L; normal val-
ues: 0.150–0.450) only slightly decreasing during
bisphosphonate treatment. Joints movements are regu-
lar except for functional limitations of elbow extension
and forearms pronation. On the basis of the radiolog-
ical signs, we addressed the molecular investigation
towards the IFITM5 gene and confirmed the presence
of the pathognomonic mutation, c.-14C>T, in het-
erozygosity (Fig. 1B). Parental DNAs, obtained from
peripheral blood leukocytes, did not bear the muta-
tion (data not shown), thus confirming its de novo
occurrence.
A large proportion of spontaneous mutations occur
at 5-methyl-cytosines at CpG dinucleotide sites which
undergo deamination [8]. In order to test whether the
nucleotide c.-14C in IFITM5 gene may be a muta-
tional hotspot, we investigated its methylation state in
sperm DNA and a few somatic tissues, as described
in materials and methods. The methylation rate (p)
for any CpG within the sequenced region was calcu-
lated as p = Hminor /(Hmajor +Hminor ) as described
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[9]. Sequence analysis revealed that c.-14C is 100%
methylated in sperm and leukocytes while it appears
≥80% methylated in bone marrow and in fibroblasts
(Table 1). We also observed that, among the differ-
ent DNAs tested, fibroblast DNA showed the lowest
methylation levels within the IFITM5 promoter region.
Patient’s data and biological samples were obtained
after fully informed parental consent according to the
procedures established by the local bioethical commit-
tee. Genomic DNA samples from leukocytes, sperm,
bone marrow, cultured skin fibroblasts, were prepared
using PureGene DNA isolation kits (Gentra Systems,
Minneapolis, MN, USA).
2.1. Mutation detection
Heterozygosity of the proband for the c.-14C>T
transition was revealed by direct sequencing of ampli-
fied genomic DNA obtained from a peripheral blood
sample.
2.2. Methylation analysis
Total genomic DNA was extracted from cultured
skin fibroblasts, leukocytes, sperm and bone mar-
row, obtained from six healthy subjects. In detail,
two male subjects were investigated for leukocyte,
sperm, bone marrow and fibroblast DNA; two addi-
tional male individuals were investigated for leukocyte
and sperm DNA only; two female subjects were inves-
tigated for leukocyte, bone marrow and fibroblast
DNA. DNA was sodium-bisulfite modified with an
Epitect kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s instructions. For each bisulfite
treatment we used 1 g of DNA. Briefly, in this reac-
tion all unmethylated cytosines are deaminated to be
converted into uracil bases, while 5-methylcytosines
remain unaltered. Treated DNAs were subsequently
amplified (primer sequences available upon request).
The PCR products spanning the c.-302 to c.186 region
of IFITM5 gene were then purified and sequenced by
DTCS quick start mix on a CEQ 8800 Genetic Analysis
System (Beckman Coulter, Brea, CA, USA).
3. Discussion
OI is traditionally recognized as a collagen disorder.
Mutations in the genes coding for type I collagen are
responsible for the great majority of AD forms, while
mutations in genes whose products are involved in
post-translational modifications, folding, chaperoning,
cross-linking of type I collagen have been associated
to both recessive and dominant rarer forms of OI [2].
AD OI type V is not a collagen disorder and it features
distinctive defects in bone mineralization [3]. OI type
V has been associated to a single recurrent mutation in
IFITM5 gene. The pathophysiological role of IFITM5
gene product, a transmembrane protein named BRIL
highly expressed in osteoblasts during mineralization,
is just starting to get clarified. Recently a missense
mutation within IFITM5 was characterized in a OI
patient with a distinctive clinical phenotype [10]. The
study results suggest a regulatory role of BRIL over
the production of Pigment Epithelium-Derived Factor,
a multifunctional protein which plays a crucial role in
bone mineralization, and which is absent in a recessive
clinical form, OI type VI [11]. Further investigations
hopefully will shed light over the relationship between
Pigment Epithelium-Derived Factor and BRIL and the
discovery of new mutations in their respective genes
will help us understand the connection between types
V and VI OI.
All the type V OI cases reported are sporadic and
belong to different ethnic groups; the above observa-
tions suggest that nucleotide c.-14C in the 5′ UTR
of IFITM5 is a mutational hotspot. Evidence from
both evolutionary studies and human diseases show
that methylated CpG sequences may undergo deam-
ination and represent mutational hotspots [12]. Our
data demonstrate that the recurrent de novo mutation
causing type V OI involves deamination at a CpG dinu-
cleotide, which is 100% methylated in male germ cells.
The same mutational mechanism is responsible for the
highly recurrent c.1138G>A FGFR3 gene mutation,
which causes achondroplasia (OMIM 100800). Sper-
matogonial mutations in achondroplasia are the most
common cause; a paternal age effect has been inferred,
owing to the increasing number of DNA replication
cycles, which spermatogonia undergo before embark-
ing on the meiotic divisions that lead to mature sperm
[13]. It would be interesting to track the parental origin
of IFITM5 c.-14C-T mutations to investigate if there
is a paternal-age effect.
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